1. American Congress of Obstetricians and Gynecologists. Polycystic ovary syndrome. Obstet Gynecol. 2009; 114, 936–949.
2. Sirmans, SM, Pate, KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013; 6, 1–13.
3. Hart, R, Doherty, DA. The potential implications of a PCOS diagnosis on a woman’s long-term health using data linkage. J Clin Endocrinol Metab. 2015; 100, 911–919.
4. Joham, AE, Ranasinha, S, Zoungas, S, Moran, L, Teede, HJ. Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2014; 99, E447–E452.
5. Nader, S. Infertility and pregnancy in women with polycystic ovary syndrome. Minerva Endocrinol. 2010; 35, 211–225.
6. Group TREA-sPCW. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19, 41–47.
7. Azziz, R, Carmina, E, Dewailly, D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009; 91, 456–488.
8. Abbott, DH, Dumesic, DA, Franks, S. Developmental origin of polycystic ovary syndrome – a hypothesis. J Endocrinol. 2002; 174, 1–5.
9. Abbott, DH, Nicol, LE, Levine, JE, Xu, N, Goodarzi, MO, Dumesic, DA. Nonhuman primate models of polycystic ovary syndrome. Mol Cell Endocrinol. 2013; 373, 21–28.
10. Padmanabhan, V, Veiga-Lopez, A. Animal models of the polycystic ovary syndrome phenotype. Steroids. 2013; 78, 734–740.
11. van Houten, EL, Kramer, P, McLuskey, A, Karels, B, Themmen, AP, Visser, JA. Reproductive and metabolic phenotype of a mouse model of PCOS. Endocrinology. 2012; 153, 2861–2869.
12. Comim, FV, Hardy, K, Robinson, J, Franks, S. Disorders of follicle development and steroidogenesis in ovaries of androgenised foetal sheep. J Endocrinol. 2015; 225, 39–46.
13. Barnes, RB, Rosenfield, RL, Ehrmann, DA, et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab. 1994; 79, 1328–1333.
14. Hague, WM, Adams, J, Rodda, C, et al. The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives. Clin Endocrinol (Oxf). 1990; 33, 501–510.
15. Morishima, A, Grumbach, MM, Simpson, ER, Fisher, C, Qin, K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995; 80, 3689–3698.
16. Rosenfield, RL. The diagnosis of polycystic ovary syndrome in dolescents. Pediatrics. 2015; 136, 1154–1165.
17. Kamangar, F, Okhovat, JP, Schmidt, T, et al. Polycystic ovary syndrome: special diagnostic and therapeutic considerations for children. Pediatr Dermatol. 2015; 32, 571–578.
18. Harden, KA, Cowan, PA, Velasquez-Mieyer, P, Patton, SB. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents. J Am Acad Nurse Pract. 2007; 19, 368–377.
19. Harris-Glocker, M, Davidson, K, Kochman, L, Guzick, D, Hoeger, K. Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin. Fertil Steril. 2010; 93, 1016–1019.
20. Hoeger, K, Davidson, K, Kochman, L, Cherry, T, Kopin, L, Guzick, DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab. 2008; 93, 4299–4306.
21. Lass, N, Kleber, M, Winkel, K, Wunsch, R, Reinehr, T. Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls. J Clin Endocrinol Metab. 2011; 96, 3533–3540.
22. Barrett, ES, Parlett, LE, Redmon, JB, Swan, SH. Evidence for sexually dimorphic associations between maternal characteristics and anogenital distance, a marker of reproductive development. Am J Epidemiol. 2014; 179, 57–66.
23. Salazar-Martinez, E, Romano-Riquer, P, Yanez-Marquez, E, Longnecker, MP, Hernandez-Avila, M. Anogenital distance in human male and female newborns: a descriptive, cross-sectional study. Environ Health. 2004; 3, 8.
24. Banszegi, O, Altbacker, V, Bilko, A. Intrauterine position influences anatomy and behavior in domestic rabbits. Physiol Behav. 2009; 98, 258–262.
25. Fouqueray, TD, Blumstein, DT, Monclus, R, Martin, JG. Maternal effects on anogenital distance in a wild marmot population. PloS One. 2014; 9, e92718.
26. Hotchkiss, AK, Lambright, CS, Ostby, JS, Parks-Saldutti, L, Vandenbergh, JG, Gray, LE Jr. Prenatal testosterone exposure permanently masculinizes anogenital distance, nipple development, and reproductive tract morphology in female Sprague-Dawley rats. Toxicol Sci. 2007; 96, 335–345.
27. Banszegi, O, Altbacker, V, Ducs, A, Bilko, A. Testosterone treatment of pregnant rabbits affects sexual development of their daughters. Physiol Behav. 2010; 101, 422–427.
28. Recabarren, SE, Padmanabhan, V, Codner, E, et al. Postnatal developmental consequences of altered insulin sensitivity in female sheep treated prenatally with testosterone. Am J Physiol Endocrinol Metabol. 2005; 289, E801–E806.
29. Manikkam, M, Crespi, EJ, Doop, DD, et al. Fetal programming: prenatal testosterone excess leads to fetal growth retardation and postnatal catch-up growth in sheep. Endocrinology. 2004; 145, 790–798.
30. Abbott, AD, Colman, RJ, Tiefenthaler, R, Dumesic, DA, Abbott, DH. Early-to-mid gestation fetal testosterone increases right hand 2D:4D finger length ratio in polycystic ovary syndrome-like monkeys. PloS One. 2012; 7, e42372.
31. Sanchez-Ferrer, ML, Mendiola, J, Hernandez-Penalver, AI, et al. Presence of polycystic ovary syndrome is associated with longer anogenital distance in adult Mediterranean women. Hum Reprod. 2017; 32, 2315–2323.
32. Wu, Y, Zhong, G, Chen, S, Zheng, C, Liao, D, Xie, M. Polycystic ovary syndrome is associated with anogenital distance, a marker of prenatal androgen exposure. Hum Reprod. 2017; 32, 937–943.
33. Mendiola, J, Roca, M, Minguez-Alarcon, L, et al. Anogenital distance is related to ovarian follicular number in young Spanish women: a cross-sectional study. Environ Health. 2012; 11, 90.
34. Mira-Escolano, MP, Mendiola, J, Minguez-Alarcon, L, et al. Longer anogenital distance is associated with higher testosterone levels in women: a cross-sectional study. BJOG. 2014; 121, 1359–1364.
36. Callegari, C, Everett, S, Ross, M, Brasel, JA. Anogenital ratio: measure of fetal virilization in premature and full-term newborn infants. J Pediatr. 1987; 111, 240–243.
37. Caanen, MR, Kuijper, EA, Hompes, PG, et al. Mass spectrometry methods measured androgen and estrogen concentrations during pregnancy and in newborns of mothers with polycystic ovary syndrome. Eur J Endocrinol. 2016; 174, 25–32.
38. Barrett, ES, Sathyanarayana, S, Janssen, S, et al. Environmental health attitudes and behaviors: findings from a large pregnancy cohort study. Eur J Obstet Gynecol Reprod Biol. 2014; 176, 119–125.
39. Swan SH, Sathyanarayana S, Barrett ES, et al. First-trimester phthalate exposure is linked to shorter anogenital distance in newborn boys. Human Reprod. 2015; 30, 963–972.
40. Taponen, S, Ahonkallio, S, Martikainen, H, et al. Prevalence of polycystic ovaries in women with self-reported symptoms of oligomenorrhoea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. Hum Reprod. 2004; 19, 1083–1088.
41. Teede, HJ, Joham, AE, Paul, E, et al. Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity. 2013; 21, 1526–1532.
42. West, S, Lashen, H, Bloigu, A, et al. Irregular menstruation and hyperandrogenaemia in adolescence are associated with polycystic ovary syndrome and infertility in later life: Northern Finland Birth Cohort 1986 study. Hum Reprod. 2014; 29, 2339–2351.
43. Day, FR, Hinds, DA, Tung, JY, et al. Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome. Nat Commun. 2015; 6, 8464.
44. Dunaif, A. Perspectives in polycystic ovary syndrome: from hair to eternity. J Clin Endocrinol Metab. 2016; 101, 759–768.
45. Sathyanarayana S, Grady R, Redmon JB, et al. Anogenital distance and penile width measurements in The Infant Development and the Environment Study (TIDES): methods and predictors. J Pediatr Urol. 2015; 11, 76.e1–6.
46. Swan, SH. Environmental phthalate exposure in relation to reproductive outcomes and other health endpoints in humans. Environ Res. 2008; 108, 177–184.
47. Barrett, E, Hoeger, K, Sathyanarayana, S, Redmon, JB, Nguyen, RH, Swan, SH. Anogenital distance, a biomarker of prenatal androgen exposure, is longer among newborn daughters of women with polycystic ovary syndrome (PCOS), 2016. Endocrine Society (ENDO): Boston, MA.
48. Barrett ES, Parlett LE, Sathyanarayana S, Redmon JB, Nguyen RH, Swan SH. Prenatal Stress as a Modifier of Associations between Phthalate Exposure and Reproductive Development: results from a Multicentre Pregnancy Cohort Study. Paediatr Perinat Epidemiol. 2016; 30, 105–114.
49. Sir-Petermann, T, Maliqueo, M, Angel, B, Lara, HE, Perez-Bravo, F, Recabarren, SE. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod. 2002; 17, 2573–2579.
50. Barry, JA, Kay, AR, Navaratnarajah, R, et al. Umbilical vein testosterone in female infants born to mothers with polycystic ovary syndrome is elevated to male levels. J Obstet Gynaecol. 2010; 30, 444–446.
51. Adams, J, Franks, S, Polson, DW, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet. 1985; 2, 1375–1379.
52. Padmanabhan, V, Veiga-Lopez, A. Reproduction symposium: developmental programming of reproductive and metabolic health. J Anim Sci. 2014; 92, 3199–3210.
53. Abbott, DH, Dumesic, DA, Lewis, KC, et al. Naturally occurring hyperandrogenism and intermittent menstrual cycles in female rhesus monkeys. Endocr Rev. 2012; 33(Suppl), MON-16.
54. Bornehag, CG, Carlstedt, F, Jonsson, BA, et al. Prenatal phthalate exposures and anogenital distance in Swedish boys. Environ Health Perspect. 2014; 123, 101–107.
55. Suzuki, Y, Yoshinaga, J, Mizumoto, Y, Serizawa, S, Shiraishi, H. Foetal exposure to phthalate esters and anogenital distance in male newborns. Int J Androl. 2012; 35, 236–244.
56. Baron-Cohen, S, Auyeung, B, Norgaard-Pedersen, B, et al. Elevated fetal steroidogenic activity in autism. Mol Psychiatry. 2015; 20, 369–376.
57. Baron-Cohen, S, Knickmeyer, RC, Belmonte, MK. Sex differences in the brain: implications for explaining autism. Science. 2005; 310, 819–823.
58. Kosidou, K, Dalman, C, Widman, L, et al. Maternal polycystic ovary syndrome and the risk of autism spectrum disorders in the offspring: a population-based nationwide study in Sweden. Mol Psychiatry. 2015; 21, 1441–1448.
59. Palomba, S, Marotta, R, Di Cello, A, et al. Pervasive developmental disorders in children of hyperandrogenic women with polycystic ovary syndrome: a longitudinal case-control study. Clin Endocrinol. 2012; 77, 898–904.
60. Baron-Cohen, S. The essential difference: the truth about the male and female brain. 2003. Basic Books: New York.
61. Goy, RW, Bercovitch, FB, McBrair, MC. Behavioral masculinization is independent of genital masculinization in prenatally androgenized female rhesus macaques. Horm Behav. 1988; 22, 552–571.
62. Thornton, J, Goy, RW. Female-typical sexual behavior of rhesus and defeminization by androgens given prenatally. Horm Behav. 1986; 20, 129–147.
63. Dokras, A, Clifton, S, Futterweit, W, Wild, R. Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2012; 97, 225–230.e222.
64. Hu, M, Richard, JE, Maliqueo, M, et al. Maternal testosterone exposure increases anxiety-like behavior and impacts the limbic system in the offspring. Proc Natl Acad Sci U S A. 2015; 112, 14348–14353.
65. Pasterski, V, Acerini, CL, Dunger, DB, et al. Postnatal penile growth concurrent with mini-puberty predicts later sex-typed play behavior: evidence for neurobehavioral effects of the postnatal androgen surge in typically developing boys. Horm Behav. 2015; 69, 98–105.
66. Kanova, N, Bicikova, M. Hyperandrogenic states in pregnancy. Physiol Res. 2011; 60, 243–252.
67. Xita, N, Tsatsoulis, A. Genetic variants of sex hormone-binding globulin and their biological consequences. Mol Cell Endocrinol. 2010; 316, 60–65.
68. Maliqueo, M, Lara, HE, Sanchez, F, Echiburu, B, Crisosto, N, Sir-Petermann, T. Placental steroidogenesis in pregnant women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2013; 166, 151–155.
69. Palomba, S, Russo, T, Falbo, A, et al. Macroscopic and microscopic findings of the placenta in women with polycystic ovary syndrome. Hum Reprod. 2013; 28, 2838–2847.
70. Palomba, S, Russo, T, Falbo, A, et al. Decidual endovascular trophoblast invasion in women with polycystic ovary syndrome: an experimental case-control study. J Clin Endocrinol Metab. 2012; 97, 2441–2449.
71. Govind, A, Obhrai, MS, Clayton, RN. Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. J Clin Endocrinol Metab. 1999; 84, 38–43.
72. Hague, WM, Adams, J, Reeders, ST, Peto, TE, Jacobs, HS. Familial polycystic ovaries: a genetic disease? Clin Endocrinol (Oxf). 1988; 29, 593–605.
73. Lunde, O, Magnus, P, Sandvik, L, Hoglo, S. Familial clustering in the polycystic ovarian syndrome. Gynecol Obstet Invest. 1989; 28, 23–30.
74. Puttabyatappa, M, Cardoso, RC, Padmanabhan, V. Effect of maternal PCOS and PCOS-like phenotype on the offspring’s health. Mol Cell Endocrinol. 2015; 435, 29–39.
75. Abbott, DH, Levine, JE, Dumesic, DA. Translational insight into polycystic ovary syndrome (PCOS) from female monkeys with PCOS-like traits. Curr Pharm Des. 2016; 22, 5625–5633.
76. Cole, B, Hensinger, K, Maciel, GA, Chang, RJ, Erickson, GF. Human fetal ovary development involves the spatiotemporal expression of p450c17 protein. J Clin Endocrinol Metab. 2006; 91, 3654–3661.
77. Ellinwood, WE, McClellan, MC, Brenner, RM, Resko, JA. Estradiol synthesis by fetal monkey ovaries correlates with antral follicle formation. Biol Reprod. 1983; 28, 505–516.
78. Fowler, PA, Anderson, RA, Saunders, PT, et al. Development of steroid signaling pathways during primordial follicle formation in the human fetal ovary. J Clin Endocrinol Metab. 2011; 96, 1754–1762.
79. Crisosto, N, Echiburu, B, Maliqueo, M, et al. Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular mass of their daughters. Fertil Steril. 2012; 97, 218–224.
80. Crisosto, N, Codner, E, Maliqueo, M, et al. Anti-Mullerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007; 92, 2739–2743.
81. Dumesic, DA, Abbott, DH, Eisner, JR, Goy, RW. Prenatal exposure of female rhesus monkeys to testosterone propionate increases serum luteinizing hormone levels in adulthood. Fertil Steril. 1997; 67, 155–163.
82. Stadtmauer, LA, Wong, BC, Oehninger, S. Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome – beyond ovulation induction. Hum Reprod. 2002; 17, 3016–3026.
83. Carlsen, SM, Vanky, E. Metformin influence on hormone levels at birth, in PCOS mothers and their newborns. Hum Reprod. 2010; 25, 786–790.
84. Vanky, E, Salvesen, KA, Heimstad, R, Fougner, KJ, Romundstad, P, Carlsen, SM. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod. 2004; 19, 1734–1740.